Atlas Trials

FutureGen Biopharmaceutical (Beijing) Co., Ltd

6 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch FutureGen Biopharmaceutical (Beijing) Co., Ltd

RecordFirmDate
A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma (NCT07758491)FutureGen Biopharmaceutical (Beijing) Co., Ltd2026-08-30
A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors (NCT07704866)FutureGen Biopharmaceutical (Beijing) Co., Ltd2026-07-30
A Study of FG-B901 Monotherapy or Combination With Chemotherapy in Advanced or Metastatic Solid Tumors (NCT07623707)FutureGen Biopharmaceutical (Beijing) Co., Ltd2026-07-01
A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer (NCT07383922)FutureGen Biopharmaceutical (Beijing) Co., Ltd2026-02-28
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. (NCT06177041)FutureGen Biopharmaceutical (Beijing) Co., Ltd2023-12-25
Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China (NCT04894825)FutureGen Biopharmaceutical (Beijing) Co., Ltd2021-06-11

Track FutureGen Biopharmaceutical (Beijing) Co., Ltd automatically

Every clearance here is in the API, with alerts when new ones post.